GAVISCON 250 - LEMON FLAVOUR
Country: Ireland
Language: English
Source: HPRA (Health Products Regulatory Authority)
Summary of Product characteristics
(SPC)
19-04-2024
Some documents for this product are not currently available, you can send a request to our customer service and we will notify you as soon as we are able to obtain them.
Send request.
Send request.
Active ingredient:
ALGINIC ACID SODIUM BICARBONATE ALUMINIUM HYDROXIDE DRIED MAGNESIUM TRISILICATE
Available from:
Reckitt Benckiser Ireland Ltd
Pharmaceutical form:
Tablets Chewable
Authorization date:
1996-01-03
Summary of Product characteristics
PART II
SUMMARY OF PRODUCT CHARACTERISTICS
1 NAME OF THE MEDICINAL PRODUCT
Gaviscon 250 Lemon Flavour
2 QUALITATIVE AND QUANTITATIVE COMPOSITION
Each tablet contains 250 mg alginic acid (Ph. Eur.), 85 mg
sodium bicarbonate (Ph. Eur.), 50 mg dried aluminium
hydroxide (Ph. Eur.) and 12.5 mg magnesium trisilicate (Ph. Eur.).
For excipients, see 6.1.
3 PHARMACEUTICAL FORM
Chewable tablet.
Circular matt, off-white to cream chewable tablet, with a lemon
odour.
4 CLINICAL PARTICULARS
4.1 THERAPEUTIC INDICATIONS
Relief of heartburn and indigestion.
4.2 POSOLOGY AND METHOD OF ADMINSTRATION
For oral administration, after being thoroughly
chewed. The dose can be rinsed down with a quantity of water.
Adults and children over 12 years: Two tablets as required.
Children under 12 years: Not recommended.
4.3 CONTRAINDICATIONS
None known.
4.4 SPECIAL WARNINGS AND SPECIAL PRECAUTIONS FOR USE
Sodium content of a tablet is 23.5 mg (1.02 mmol). This may
be of importance when a highly restricted salt diet is
required as in some renal and cardiovascular conditions.
Aluminium hydroxide may lead to a phosphate depletion syndrome,
particularly in patients on a low phosphate diet,
e.g. malnutrition.
Aluminium may cause constipation due to
its astringent action; this effect may be balanced by
the cathartic effect of the
magnesium salts.
Magnesium salts may cause central nervous system depression in
the presence of renal insufficiency and should not be
used in patients with renal failure.
IRISH MEDICINES BOARD
________________________________________________________________________________________________________________________
_Date Issued 22/09/2005_
_CRN 2014941_
_page number: 1_
4.5 INTERACTION WITH OTHER MEDICINAL PRODUCTS AND OTHER FORMS OF INTERACTION
Aluminium hydroxide may form complexes with certain
drugs including those used in pregnancy, e.g. tetracyclines,
digoxin and vitamin
Read the complete document
